Search Results

You are looking at 51 - 60 of 551 items for :

  • neuroendocrine cancer x
  • All content x
Clear All
Free access

O Hentic, P Hammel, A Couvelard, V Rebours, M Zappa, M Palazzo, F Maire, G Goujon, A Gillet, P Lévy, and P Ruszniewski

neuroendocrine tumors . Cancer 92 1101 – 1107 . ( doi:10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V ). Hainsworth JD Spigel DR Litchy S Greco FA 2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly

Open access

Gina Chia-Yi Chu, Haiyen E Zhau, Ruoxiang Wang, André Rogatko, Xu Feng, Majd Zayzafoon, Youhua Liu, Mary C Farach-Carson, Sungyong You, Jayoung Kim, Michael R Freeman, and Leland W K Chung

previous reports showing that cancer cells undergoing EMT expressed stem cell characteristics ( Kong et al . 2011 ). The emergence of an neuroendocrine phenotype in the LNCaP as well as ARCaP M cell backgrounds in response to RANKL–RANK signaling has not

Free access

Kimberly Kamp, Brenda Gumz, Richard A Feelders, Dik J Kwekkeboom, Gregory Kaltsas, Frederico P Costa, and Wouter W de Herder

Introduction Neuroendocrine tumors (NETs) form a heterogeneous group of relatively rare neoplasms that originate from different types of neuroendocrine cells ( Modlin et al . 2008 ). The incidence and prevalence of gastroenteropancreatic NETs (GEP

Restricted access

Corinne Gérard, Marie Lagarde, Flora Poizat, Sandrine Oziel-Taieb, Vincent Garcia, Catherine Roche, Patricia Niccoli, Anne Barlier, and David Romano

capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology 59 637 – 642 . ( ) Beauchamp RD Coffey Jr RJ

Free access

Judith A Gilbert, Laura J Adhikari, Ricardo V Lloyd, Joseph Rubin, Paul Haluska, Joan M Carboni, Marco M Gottardis, and Matthew M Ames

effectors and regulators have been under development for other forms of cancer. Targets of these new inhibitor/antibody chemotherapeutic pharmaceuticals that might play a role in the biology of neuroendocrine tumors were therefore assessed in a collection of

Free access

Viola Baradari, Alexander Huether, Michael Höpfner, Detlef Schuppan, and Hans Scherübl

. Höpfner M , Sutter AP, Huether A, Ahnert-Hilger G & Scherübl H 2004 A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodoben-zylguanidine. BMC Cancer 4 23

Free access

S Crnalic, E Hörnberg, P Wikström, U H Lerner, Å Tieva, O Svensson, A Widmark, and A Bergh

Introduction Metastasis to the bone is one of the most clinically important features of prostate cancer (PC). The standard therapy for bone metastases is androgen ablation where circulating androgens are reduced by surgical or medical castration

Free access

Roberto Valente, Alastair J Hayes, Sven-Petter Haugvik, Per Hedenström, Darko Siuka, Emilie Korsæth, Daniel Kämmerer, Stuart M Robinson, Patrick Maisonneuve, Gianfranco Delle Fave, Bjorn Lindkvist, and Gabriele Capurso

slightly more prevalent in cases (36.8% vs 30.2% P  = 0.09). A 1st degree family history of specific cancer sites was also not significantly different ( Table 2 ). No cases or controls reported a family history of neuroendocrine tumor (NET). At multiple

Free access

Shani Avniel-Polak, Gil Leibowitz, Victoria Doviner, David J Gross, and Simona Grozinsky-Glasberg

tyrosine kinase signaling and activates Akt . Cancer Research 66 1500 – 1508 . 10.1158/0008-5472.CAN-05-2925 16452206 Oberg K 2005 Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and

Free access

Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, and Ashley Grossman

Introduction There are numerous specific guidelines developed for the relatively common malignant endocrine tumours such as thyroid cancer and gastrointestinal neuroendocrine tumours (NETs) ( Haugen et al. 2016 , Pavel et al. 2016 ), but